Objective:

To outline a practical early-phase approach to drug substance (DS) development within the CMC framework, emphasizing integration and pragmatism.

Key Findings:

• Integration of process development, analytical strategy, and manufacturing is crucial for successful CMC.
• Early-phase development should prioritize risk-based decisions and fit-for-purpose methods.
• Limited batch data in early phases allows for flexibility in specifications and control strategies.

Interpretation:

A balanced, integrated approach to early-phase CMC can enhance product quality and regulatory compliance while managing risks effectively.

Limitations:

• Limited batch history may restrict the ability to define critical process parameters.
• Time constraints may hinder comprehensive characterization of complex molecules.

Conclusion:

An integrated and pragmatic approach to early-phase CMC supports efficient drug development and regulatory alignment.